Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reduction of Early mortALITY in HIV-infected African adults and children starting antiretroviral therapy: a randomised controlled trial

Next Previous
X
Search
Trial Profile

Reduction of Early mortALITY in HIV-infected African adults and children starting antiretroviral therapy: a randomised controlled trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary) ; Abacavir; Albendazole; Azithromycin; Cotrimoxazole; Efavirenz; Emtricitabine; Fluconazole; Isoniazid; Isoniazid/pyridoxine; Lamivudine; Nevirapine; Tenofovir dipivoxil fumarate; Zidovudine
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms REALITY

    • Most Recent Events

    • 10 Mar 2021 Results evalauting role of socioeconomic indices in immune activation among PLWH in Malawi, presented at the 28th Conference on Retroviruses and Opportunistic Infections
    • 07 Mar 2018 Results assessing effect of 12- week raltegravir intensification presented at the 25th Conference on Retroviruses and Opportunistic Infections
    • 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top